Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection

(2023) Harry L A Janssen et al.   GUT

Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB

(2022) Man-Fung Yuen et al.   JOURNAL OF HEPATOLOGY

Continued suppression of viral markers observed following discontinuation of nucleos (t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729

(2022) Man-Fung Yuen et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study

(2022) Kosh Agarwal et al.   JOURNAL OF HEPATOLOGY

Plasma and Liver Pharmacokinetics of the N-Acetylgalactosamine Short Interfering RNA JNJ-73763989 in Recombinant Adeno-Associated–Hepatitis B Virus–Infected Mice

(2022) Louis Sandra et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

(2022) Man-Fung Yuen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379

(2020) Jan Martin Berke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

JNJ-56136379, an HBV Capsid Assembly Modulator, is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients with Chronic Infection

(2020) Fabien Zoulim et al.   GASTROENTEROLOGY

Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A–H clinical isolates and core site-directed mutants in vitro

(2020) Thierry Verbinnen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Hepatitis B Surface Antigen Seroclearance: Immune Mechanisms, Clinical Impact, Importance for Drug Development

(2020) Issam Tout et al.   JOURNAL OF HEPATOLOGY

Virology analysis of chronic hepatitis B virus–infected patients treated for 28 days with JNJ‐56136379 monotherapy

(2020) Thierry Verbinnen et al.   JOURNAL OF VIRAL HEPATITIS

Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment

(2020) Edward Gane et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data

(2020) Harry Janssen et al.   JOURNAL OF HEPATOLOGY

Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

(2019) Joris Vandenbossche et al.   ADVANCES IN THERAPY

Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure

(2019) Tarik Asselah et al.   Lancet Gastroenterology & Hepatology

Hepatitis B virus infection

(2018) Man-Fung Yuen et al.   Nature Reviews Disease Primers

Hepatitis B cure: From discovery to regulatory approval

(2017) Anna S. Lok et al.   HEPATOLOGY

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

(2017) Pietro Lampertico et al.   JOURNAL OF HEPATOLOGY

Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis

(2015) Anna S.F. Lok et al.   HEPATOLOGY

Interferon Therapy of Chronic Hepatitis B

(2014) Maurizia Rossana Brunetto et al.   INTERVIROLOGY

Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with peginterferon alfa-2a and adefovir

(2013) R Bart Takkenberg et al.   ANTIVIRAL THERAPY